124 related articles for article (PubMed ID: 1641370)
1. The relationship between cardiovascular complications of estrogen therapy and fibrinolysis in patients with prostatic cancer.
Hasui Y; Marutsuka K; Nishi S; Kitada S; Osada Y; Sumiyoshi A
Prostate; 1992; 21(1):35-9. PubMed ID: 1641370
[TBL] [Abstract][Full Text] [Related]
2. Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products.
van Hinsbergh VW; Bauer KA; Kooistra T; Kluft C; Dooijewaard G; Sherman ML; Nieuwenhuizen W
Blood; 1990 Dec; 76(11):2284-9. PubMed ID: 1701665
[TBL] [Abstract][Full Text] [Related]
3. Fibrinolysis and coagulation in patients with infectious disease and sepsis.
Philippé J; Offner F; Declerck PJ; Leroux-Roels G; Vogelaers D; Baele G; Collen D
Thromb Haemost; 1991 Mar; 65(3):291-5. PubMed ID: 1904655
[TBL] [Abstract][Full Text] [Related]
4. Plasminogen activators and inhibitors in normal late pregnancy, postpartum and in the postnatal period.
Koh CL; Viegas OA; Yuen R; Chua SE; Ng BL; Ratnam SS
Int J Gynaecol Obstet; 1992 May; 38(1):9-18. PubMed ID: 1348996
[TBL] [Abstract][Full Text] [Related]
5. Depression of tissue-type plasminogen activator and enhancement of urokinase-type plasminogen activator as an expression of local inflammation.
Brommer EJ; Dooijewaard G; Dijkmans BA; Breedveld FC
Thromb Haemost; 1992 Aug; 68(2):180-4. PubMed ID: 1412164
[TBL] [Abstract][Full Text] [Related]
6. [Plasminogen activators (t-PA and u-PA) and other fibrinolysis parameters in patients with atherosclerosis obliterans and diabetic macroangiopathy].
Zalewska-Rydzkowska D; Rość D; Ponikowska I; Michalski A; Graczykowska-Koczorowska A; Rydzkowski M
Pol Merkur Lekarski; 2001 Nov; 11(65):414-7. PubMed ID: 11852811
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen activators t-PA, u-PA and its inhibitor (PAI) in normal males and females.
Koh SC; Yuen R; Viegas OA; Chua SE; Ng BL; Sen DK; Ratnam SS
Thromb Haemost; 1991 Nov; 66(5):581-5. PubMed ID: 1803623
[TBL] [Abstract][Full Text] [Related]
9. Selected parameters of fibrinolysis system in patients with dermatitis herpetiformis.
Wankiewicz A; Iwan-Zietek I; Kotschy M; Gwieździński Z
Med Sci Monit; 2002 Mar; 8(3):CR189-92. PubMed ID: 11887034
[TBL] [Abstract][Full Text] [Related]
10. The fibrinolytic system components are increased in systemic sclerosis and modulated by Alprostadil (alpha1 ciclodestryn).
Bandinelli F; Bartoli F; Perfetto E; Del Rosso A; Moggi-Pignone A; Guiducci S; Cinelli M; Fatini C; Generini S; Gabrielli A; Giacomelli R; Maddali Bongi S; Abbate R; Del Rosso M; Matucci Cerinic M
Clin Exp Rheumatol; 2005; 23(5):671-7. PubMed ID: 16173244
[TBL] [Abstract][Full Text] [Related]
11. Lack of correlation between blood fibrinolysis and the immediate or post-operative blood loss in transurethral resection of the prostate.
Nielsen JD; Gram J; Fabrin K; Holm-Nielsen A; Jespersen J
Br J Urol; 1997 Jul; 80(1):105-10. PubMed ID: 9240188
[TBL] [Abstract][Full Text] [Related]
12. Baseline fibrinolytic state and the risk of future venous thrombosis. A prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor.
Ridker PM; Vaughan DE; Stampfer MJ; Manson JE; Shen C; Newcomer LM; Goldhaber SZ; Hennekens CH
Circulation; 1992 May; 85(5):1822-7. PubMed ID: 1572039
[TBL] [Abstract][Full Text] [Related]
13. Regulatory effects of estetrol on the endothelial plasminogen pathway and endothelial cell migration.
Montt-Guevara MM; Palla G; Spina S; Bernacchi G; Cecchi E; Campelo AE; Shortrede JE; Canu A; Simoncini T
Maturitas; 2017 May; 99():1-9. PubMed ID: 28364860
[TBL] [Abstract][Full Text] [Related]
14. Changes in plasminogen activator inhibitor 1 and tissue-type plasminogen activator during exercise in patients with coronary artery disease.
Rydzewski A; Sakata K; Kobayashi A; Yamazaki N; Urano T; Takada Y; Takada A
Haemostasis; 1990; 20(5):305-12. PubMed ID: 2127039
[TBL] [Abstract][Full Text] [Related]
15. [Tissue-type plasminogen activator and its inhibitor (PAI-1) in plasma in cases of non-insulin-dependent diabetes mellitus (NIDDM)].
Jokaji H; Asakura H; Saito M; Uotani C; Kumabashiri I; Morishita E; Yamazaki M; Matsuda T
Nihon Ronen Igakkai Zasshi; 1990 Nov; 27(6):699-705. PubMed ID: 2127812
[TBL] [Abstract][Full Text] [Related]
16. [Tissue plasminogen activator (T-PA) and tissue plasminogen activator inhibitor (PAI-1) in patients after head injury].
Beuth W; Kotschy M; Kasprzak HA; Rość D; Osiński P; Sniegocki M
Neurol Neurochir Pol; 1996; 30(3):427-34. PubMed ID: 8965977
[TBL] [Abstract][Full Text] [Related]
17. Analysis of fibrinolytic proteins in relation to DNA ploidy in prostate cancer.
Plas E; Carroll VA; Jilch R; Mihaly J; Vesely M; Ulrich W; Pflüger H; Binder BR
Int J Cancer; 1998 Oct; 78(3):320-5. PubMed ID: 9766566
[TBL] [Abstract][Full Text] [Related]
18. Increased plasma fibrinolysis and tissue-type plasminogen activator/tissue-type plasminogen activator inhibitor ratios after ethanol withdrawal in chronic alcoholics.
Delahousse B; Maillot F; Gabriel I; Schellenberg F; Lamisse F; Gruel Y
Blood Coagul Fibrinolysis; 2001 Jan; 12(1):59-66. PubMed ID: 11229828
[TBL] [Abstract][Full Text] [Related]
19. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
[TBL] [Abstract][Full Text] [Related]
20. Hepatic synthesis and clearance of components of the fibrinolytic system in healthy volunteers and in patients with different stages of liver cirrhosis.
Huber K; Kirchheimer JC; Korninger C; Binder BR
Thromb Res; 1991 Jun; 62(5):491-500. PubMed ID: 1910213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
